FBP1 and acute myeloid leukemia: FBP1-MV4-11 blasts were found to have significantly increased cell death (viable cells: 88.3%) and decreased expression of Ki67 (34.7%)—a biomarker for the proliferation of AML blasts—when compared to MV4-11 (viable cells: 95.6% and Ki67+: 59.1%) in vitro (Figure 3A,B).